Intestinal Pseudo-Obstruction Treatment Market Report 2026

The intestinal pseudo-obstruction treatment market size has grown strongly in recent years. It will grow from $24.74 billion in 2025 to $26.01 billion in 2026 at a compound annual growth rate (CAGR) of 5.1%. The growth in the historic period can be attributed to limited understanding of gastrointestinal motility disorders, increased hospitalization for unexplained bowel obstruction symptoms, reliance on symptomatic drug therapies, advancements in diagnostic imaging and motility testing, growth in specialist gastroenterology clinics.

The intestinal pseudo-obstruction treatment market size is expected to see strong growth in the next few years. It will grow to $33.02 billion in 2030 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to increasing research into intestinal motility disorders, growing demand for personalized ipo treatment plans, rising adoption of advanced diagnostic techniques, expansion of multidisciplinary gastroenterology care, improved clinical guidelines for rare gi disorders. Major trends in the forecast period include increasing focus on early and accurate diagnosis of ipo, growing use of multimodal symptom management strategies, rising adoption of conservative and non-surgical treatments, expansion of long-term disease management and supportive care, improved awareness of rare gastrointestinal motility disorders.

The increasing prevalence of Parkinson's disease is expected to drive the growth of the intestinal pseudo-obstruction treatment market in the coming years. Parkinson's disease is a neurodegenerative disorder that primarily impacts the dopamine-producing neurons in the substantia nigra, a specific area of the brain. Individuals with Parkinson's disease have a higher incidence of IPO because the condition affects the enteric nervous system, leading to gastrointestinal dysmotility that can cause megacolon or intestinal blockage, including acute colonic pseudo-obstruction. For example, in July 2025, Sutter Health, a US-based nonprofit healthcare network, reported that approximately 1.1 million people in the United States were living with Parkinson’s disease in 2025, with this figure expected to reach 1.2 million by 2030. Consequently, the rising prevalence of Parkinson's disease contributes to the growth of the intestinal pseudo-obstruction treatment market.

The increasing demand for personalized medicine is expected to drive the growth of the intestinal pseudo-obstruction (IPO) treatment market in the coming years. Personalized medicine utilizes genetic information to tailor treatments for individual patients. The rising demand for personalized medicine is attributed to advancements in genomics and biotechnology, as well as increasing awareness of genetic testing and precision healthcare. Personalized medicine customizes treatment for intestinal pseudo-obstruction based on a patient’s unique genetic and lifestyle factors, enhancing symptom management and therapy effectiveness. For example, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the FDA approved 16 new personalized treatments for patients with rare diseases in 2023, a notable increase from six approvals in 2022. Consequently, the growing demand for personalized medicine is driving the growth of the intestinal pseudo-obstruction (IPO) treatment market.

In May 2023, Ironwood Pharmaceuticals, a U.S.-based pharmaceutical company, acquired VectivBio Holding AG for an undisclosed amount. This acquisition is expected to enhance Ironwood's innovation pipeline and portfolio, aiming to redefine the standard of care for gastrointestinal (GI) patients and advance the treatment of GI disorders. VectivBio Holding AG is a Switzerland-based clinical-stage biotechnology company focused on treating severe, rare gastrointestinal conditions, including intestinal pseudo-obstruction (IPO).

Major companies operating in the intestinal pseudo-obstruction treatment market are F. Hoffmann-La Roche AG, Merck Sharp & Dohme Corp, Bayer AG, Sanofi S.A., AstraZeneca plc, GSK plc, Takeda Pharmaceutical Company Limited, Amgen PLC, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Mylan N.V., Biogen Inc., Penn Medicine, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd, Cipla Inc., Dr. Reddy's Laboratories Ltd., Allergan plc, Torrent Pharmaceuticals Limited, Basilea Pharmaceutica Ltd, Paratek Pharmaceuticals Inc., Melinta Therapeutics LLC, Tetraphase Pharmaceuticals Inc., Callisto Pharmaceuticals Inc.

North America was the largest region in the intestinal pseudo-obstruction treatment market in 2025. The regions covered in the intestinal pseudo-obstruction treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the intestinal pseudo-obstruction treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the intestinal pseudo-obstruction treatment market by increasing costs of imported diagnostic equipment, specialized pharmaceuticals, and hospital-grade decompression devices. These impacts are most evident in advanced diagnostic and inpatient treatment segments, particularly across asia-pacific and europe where medical technology imports are significant. Higher tariffs have increased treatment and hospitalization costs for hospitals and clinics. However, tariffs are also encouraging local production of diagnostic tools, domestic drug manufacturing, and supply chain diversification, supporting long-term market resilience.

The intestinal pseudo-obstruction treatment market research report is one of a series of new reports that provides intestinal pseudo-obstruction treatment market statistics, including intestinal pseudo-obstruction treatment industry global market size, regional shares, competitors with a intestinal pseudo-obstruction treatment market share, detailed intestinal pseudo-obstruction treatment market segments, market trends and opportunities, and any further data you may need to thrive in the intestinal pseudo-obstruction treatment industry. This intestinal pseudo-obstruction treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Intestinal pseudo-obstruction (IPO) treatment involves managing a rare gastrointestinal motility disorder that presents with symptoms resembling a mechanical bowel obstruction, despite no physical blockage being present. The goal of intestinal pseudo-obstruction treatment is to relieve symptoms, enhance intestinal motility, prevent complications, and improve overall quality of life.

The primary classes of drugs used in intestinal pseudo-obstruction treatment include antibiotics, antidepressants, and antidiarrheals. Antibiotics are a group of potent medications used to treat bacterial infections in humans and animals. Various types of treatments are available, such as medication, surgery, dietary modifications, decompression, and others, which can be administered through multiple routes, including oral, intravenous, and more. A range of diagnostic methods, including physical examination, biopsy, blood tests, gastric emptying studies, imaging tests, and others, are utilized by different end users, including clinics, hospitals, and more.

The intestinal pseudo-obstruction (IPO) treatment market consists of revenues earned by providing entities by providing surgical interventions, decompression and nutrition support. The market value includes the value of related goods sold by the service provider or included within the service offering. The intestinal pseudo-obstruction (IPO) treatment market also includes sales of narcotics, laxatives and pro-kinetics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.